Brind.

Biopharma Executive Joins GOA Therapeutics as Chief Medical Officer

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Dean Hakanson has joined GOA Therapeutics Corporation as Chief Medical Officer. Hakanson brings 40 years of experience in clinical practice and biopharma leadership, including leading U.S. Medical Affairs for Gilead Sciences during the launch of remdesivir. His previous roles included senior leadership positions at Bristol-Myers Squibb.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The appointment signals the acceleration of GOA Therapeutics Corporation's drug candidates, starting with GOA26, an investigational drug designed to lower blood alcohol concentration. Hakanson’s background in drug development and commercialization may help drive the potential launch of these new therapies.

From manilatimes.net

Who's involved

  • Gilead SciencesGilead Sciences was the company where Hakanson led U.S. Medical Affairs for the remdesivir launch.
  • Bristol-Myers SquibbBristol-Myers Squibb was one of the companies where Hakanson held senior leadership positions.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped